Maze Therapeutics details Q3 2025 results release

Maze Therapeutics, Inc. filed a current report to note it issued a press release with its financial results for the third quarter ended September 30, 2025.

Accepted by SEC EDGAR 11/06/2025 - 04:21 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Maze Therapeutics, Inc. filed a current report to note it issued a press release with its financial results for the third quarter ended September 30, 2025.

The press release, dated November 6, 2025, is furnished as Exhibit 99.1 and is designated as “furnished,” not “filed,” limiting its treatment under certain securities law liability provisions.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Maze Therapeutics (MAZE) disclose in this 8-K?

Maze Therapeutics discloses that it issued a press release reporting financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is provided for informational purposes as a furnished exhibit.

Which period’s results does Maze Therapeutics (MAZE) address in the press release?

The press release covers Maze Therapeutics’ financial results for the third quarter ended September 30, 2025. This timing helps investors align the disclosure with the company’s regular quarterly reporting cycle and understand which operating period is being discussed.

How is the Maze Therapeutics (MAZE) Q3 2025 press release provided to investors?

The company provides the Q3 2025 financial results through a press release furnished as Exhibit 99.1 to this report. Furnishing the exhibit makes the text publicly accessible through SEC records alongside other Maze Therapeutics disclosures.

Is the Maze Therapeutics (MAZE) Q3 2025 press release considered filed with the SEC?

No, the company specifies that Item 2.02 information, including Exhibit 99.1, is furnished rather than filed. This distinction affects how the press release is treated under certain liability provisions of the Securities Exchange Act and Securities Act.

When did Maze Therapeutics (MAZE) issue the Q3 2025 financial results press release?

Maze Therapeutics issued the press release on November 6, 2025. The same date appears in the exhibit description and signature block, linking the communication of third-quarter results to this specific disclosure date for investor reference.

What exhibits are included with this Maze Therapeutics (MAZE) 8-K?

The report includes Exhibit 99.1, the press release dated November 6, 2025, and Exhibit 104, the cover page interactive data file. These exhibits package the narrative results and technical XBRL data associated with the current report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001842295false00018422952025-11-062025-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 06, 2025

Maze Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42490	82-2635018
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
171 Oyster Point Blvd., Suite 300
South San Francisco, California				94080
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 850-5070

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock - par value $0.001 per share		MAZE		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Maze Therapeutics Inc. (the “Company”) issued a press release reporting its financial results for the third quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Section 11 or 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act, whether made before or after the date hereof, except as expressly set forth by reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1*		Press Release dated November 6, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	November 6, 2025	By:	/s/ Courtney Phillips
			Courtney Phillips General Counsel and Corporate Secretary